MFG
IMDX

Merit Financial Group’s Insight Molecular Diagnostics IMDX Stock Holding History

Merit Financial Group’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,600
Closed -$7.36K – 773
2023
Q2 		$7.36K Hold
1,600
– – ﹤0.01% 743
2023
Q1 		$11.3K Hold
1,600
– – ﹤0.01% 628
2022
Q4 		$10.3K Buy
+1,600
New +$17.6K ﹤0.01% 686

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Merit Financial Group's IMDX Position: Q3 2023 in Review

Merit Financial Group sold out of Insight Molecular Diagnostics (IMDX) in Q3 2023, closing a stake of 1,600 shares — an estimated $7.36K sold.

Merit Financial Group first reported a position in IMDX in Q4 2022 and held it in 3 quarters. The position peaked at $11.3K in Q1 2023. 30 funds tracked by Wall St. Rank hold IMDX as of Q3 2023.

  • Merit Financial Group reported no remaining Insight Molecular Diagnostics position as of Q3 2023 after selling out during the quarter.
  • Merit Financial Group sold 1,600 Insight Molecular Diagnostics shares in Q3 2023, an estimated $7.36K.
  • Merit Financial Group first reported a position in Insight Molecular Diagnostics in Q4 2022 and held it in 3 quarters.
  • Merit Financial Group's Insight Molecular Diagnostics position peaked at $11.3K in Q1 2023.
  • 30 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2023.

Based on Merit Financial Group's 13F filing for Q3 2023, filed 7 Nov 2023.